Showing results (381-390 of 2,259) with videos related to
Sort By:
Pageof 226
American Heart Journal|March 29, 2008
The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trialsDharam J Kumbhani, Anthony A Bavry, Apur R Kamdar, et al.JACC. Cardiovascular Interventions|February 22, 2015
Percutaneous circulatory assist devices for high-risk coronary interventionAung Myat, Niket Patel, Shana Tehrani, et al.Cardiovascular Research|January 22, 2024
Do patients benefit from omega-3 fatty acids?Samuel C R Sherratt, R Preston Mason, Peter Libby, et al.Vascular Medicine (London, England)|July 10, 2007
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic diseaseSteven R Steinhubl, Juan J Badimon, Deepak L Bhatt, et al.Journal of the American College of Cardiology|October 3, 2006
Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trialsAnthony A Bavry, Dharam J Kumbhani, Andrew N Rassi, et al.Cardiovascular Research|August 25, 2025
Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particlesSamuel C R Sherratt, Peter Libby, Richard L Dunbar, et al.European Heart Journal|January 13, 2009
Patients with peripheral arterial disease in the CHARISMA trialPatrice P Cacoub, Deepak L Bhatt, P Gabriel Steg, et al.The American Journal of Cardiology|June 4, 2017
Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary InterventionHisham A Badreldin, Danielle Carter, Bryan M Cook, et al.Thrombosis Research|May 24, 2014
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapyA Anil Timur, Gurunathan Murugesan, Li Zhang, et al.Pharmacology & Therapeutics|June 24, 2010
Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?Tobias Geisler, Meinrad Gawaz, Steven R Steinhubl, et al.Pageof 226